ArticleCureus2026
Decellularized Porcine Tendon Xenografts Provide a Viable Option in Anterior Cruciate Ligament Reconstruction.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe anterior cruciate ligament (ACL) is one of the most commonly injured ligaments, and ACL reconstruction (ACLR) is projected to steadily increase. While autografts are the gold standard, the limited harvest volume and donor site morbidity have spurred the search for viable alternatives. A decellularized porcine xenograft is currently available; therefore, we have investigated patient outcomes in a series of patients who have received this graft for ACLR.
methodsPatients were eligible for inclusion in this study if they had undergone ACLR, either primary or revision, and had received a decellularized tendon xenograft (Orthopure XT, Tissue Regenix, Leeds, UK) as the ACL graft. All patients underwent surgery by the same surgeon at the same hospital (IRCCS Ospedale Galeazzi, Milan, Italy) and followed standardized care for ACLR, including surgery and post-operative rehabilitation. The outcome data collected were the International Knee Documentation Committee (IKDC) score, Tegner-Lysholm, and visual analog scale (VAS) for pain. Outcome data were analysed using a repeated measures ANOVA, with α=0.05.
resultsOf the 29 patients who underwent ACLR, 24 (83%) were male. The mean age at surgery for male patients was 43.6 ± 9.8 years, while for women, it was 40.8 ± 15.1 years. The mean BMI was 25.8 ± 3.4 for men and 25.4 ± 2.9 for women. Follow-up was collected at a mean of 27.4 ± 9.6 months after surgery. The mean post-operative IKDC score was 94.9 ± 2.6 (95% CI: 93.9-95.9). The Tegner-Lysholm score improved from a pre-operative mean of 43.3 ± 5.7 (95% CI: 41.1-45.4) to a post-operative mean of 92.7 ± 3.6 (95% CI: 91.3-94; p<0.001). The VAS pain improved from a mean of 3.0 ± 1.4 to a post-operative mean of 0.4 ± 0.7 (p < 0.001). During the follow-up period, there was one traumatic failure (3%) and one acute infection (3%). The positive responder rate was 97%.
conclusionThe short-term follow-up outcomes in this small, retrospective cohort indicate that this decellularized xenogeneic graft, processed from porcine tendon, can provide a viable option in ACL reconstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.